IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Endo International plc (“Endo International” or the “Company”) (Nasdaq: ENDP) concerning possible violations of federal securities laws.
If you purchased shares of Endo International and want more information, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
The investigation focuses on whether Endo International and certain of its officers and/or directors violated federal securities laws. On June 8, 2017, the Food and Drug Administration (the “FDA”) requested that Endo International pull its powerful opioid painkiller Opana ER off the market due to its “high risk of abuse and potential to help spread HIV and hepatitis C.” When this information was announced, shares of Endo International lowered in value.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.